SENS-AI
APN Trading Statement Neutral

ASPEN PHARMACARE HOLDINGS LIMITED - Business Update and Trading Statement for the six months ended 31 December 2025

Aspen Pharmacare Holdings Limited
Full analysis

What this filing means

Bull case

  • The core Commercial Pharmaceuticals segment achieved robust 4% revenue growth and double-digit constant exchange rate (CER) EBITDA growth, bolstered by strong demand for Mounjaro in SA.
  • Strong balance sheet management with free cash flows expected to exceed R1.7 billion and net debt reduced to R28.6 billion (leverage <3.5x).
  • Restructuring of sterile FDF facilities is advanced, with commercial insulin production starting in Q1 2026 and full profitability expected by FY 2027.
  • The AUD 2,370 million APAC divestment is on track for May 2026 completion, which will provide substantial liquidity.
  • Management reaffirmed full-year FY 2026 guidance of double-digit growth in normalised HEPS (NHEPS) in CER, implying a strong H2 recovery.

Bear case

  • H1 2026 earnings face significant contraction, with HEPS expected to fall -33% to -38% and NHEPS down -19% to -24%.
  • Earnings were weighed down by R700 million in one-off restructuring costs and the absence of R1.5 billion in prior-period mRNA contributions.
  • The APAC divestment remains subject to shareholder approval and conditions precedent, introducing execution risk.
  • Manufacturing EBITDA benefited from a one-off R0.5 billion dispute settlement, which masks underlying performance pressure in the first half.
View original SENS announcement

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

Aspen's H1 2026 trading statement reveals a sharp earnings contraction primarily due to a high base (mRNA contracts) and R700 million in restructuring costs, but these are largely transitional in nature. While the negative HEPS guidance of -33% to -38% is stark, the underlying performance of Commercial Pharmaceuticals and the achievement of >100% cash conversion suggest the operational engine remains intact. Investor Takeaway: This is a 'reset' period where the market must weigh short-term earnings pain against the R25.5 billion (AUD 2.37bn) cash injection from the APAC divestment and a reaffirmed double-digit growth outlook for the full year. Signal-to-Price Note: The price of 109.05 ZAR cents (down 60% from its high) suggests significant negativity is already priced in, making the reaffirmed FY 2026 guidance a potential catalyst for a re-rating if H2 recovery materializes.

Evidence from the filing

  • Aspen's core Commercial Pharmaceuticals business segment delivered robust organic growth with 4% revenue growth and double-digit normalised EBITDA growth in constant exchange rates

    “Commercial Pharmaceuticals, Aspen's most material business segment, has delivered revenue growth of 4% and double-digit normalised EBITDA growth in constant exchange rates ("CER") underpinned by organic revenue growth in all three segments (Injectables, OTC and Prescription). Performance was supported by strong demand for Mounjaro in South Africa and an improved profit contribution from the reshaped business in China;”

  • The Group has significantly improved its financial position, expecting free cash flows to exceed R1.7 billion, achieving an operating cash conversion rate above 100%, and reducing net debt to R28.6 billion

    “Free cash flows (excluding dividends paid) are expected to exceed R1,7 billion, supported by an operating cash conversion rate well ahead of the Group's target of 100%, a working capital to revenue ratio of <46% and lower investment in capital expenditure; These stronger free cash flows together with favourable ZAR closing rates led to lower net debt of R28,6 billion (compared to June 2025 of R31,2 billion) and a leverage ratio (net debt to EBITDA) of below 3.5x;”

  • Operational restructuring of loss-making sterile FDF Manufacturing facilities is progressing well, with cost reductions expected to positively impact from H2 2026 onwards

    “The reshaping of the loss-making sterile FDF Manufacturing facilities in South Africa and France is well progressed with the expected benefit of the cost reductions to positively impact from H2 2026 onwards and planned to be fully realised in FY 2027;”

  • Management maintains its full-year FY 2026 guidance, forecasting double-digit growth in normalised HEPS (NHEPS) in constant exchange rates

    “The Group's FY 2026 outlook comprises the following key expectations: Double digit growth in normalised HEPS ("NHEPS") in CER;”

  • The previously announced APAC Divestment for AUD 2,370 million is on track for completion by the end of May 2026

    “The divestment of Aspen APAC ("APAC Divestment") for a gross consideration of AUD 2 370 million was announced on 29 December 2025 (https://www.sharenet.co.za/jsepdf/SENS_20251229_S515214.pdf) and subsequently discussed during a stakeholder engagement call on 15 January 2026. The APAC Divestment is subject to certain conditions precedent, including the requirement of general shareholder approval. The expected completion date is the end of May 2026.”

  • The company projects substantial declines across all key earnings metrics for H1 2026

    “NHEPS * -24% to -19% 550.4 to 586.6 724.2 HEPS -38% to -33% 400.1 to 432.4 645.4 EPS -41% to -36% 317.2 to 344.1 537.7”

  • One-off restructure costs of circa R700 million relating to these sterile FDF Manufacturing facilities have been incurred in H1 2026

    “One-off restructure costs of circa R700 million relating to these sterile FDF Manufacturing facilities have been incurred in H1 2026 and have negatively impacted earnings ("EPS") and headline earnings ("HEPS") per share.”

  • H1 2026 performance was significantly impacted by 'the absence of the prior-period mRNA contributions' (circa R1.5 billion)

    “FY 2025 operating performance was heavily weighted towards the first half ("H1 2025"), which included a contribution from the subsequently cancelled mRNA Manufacturing contract (of circa R1,5 billion), resulting in normalised Group EBITDA of R5.8 billion in H1 2025.”
Category
Trading Statement
Published
Feb 11, 2026

More on Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited (APN) share price All Aspen Pharmacare Holdings Limited SENS announcements

Related filings